Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin

Abstract

Conformational diseases include heterogeneous disorders sharing a similar pathological mechanism, leading to intracellular aggregation of proteins with toxic effects. Serpins are commonly involved in these diseases. These are structurally sensitive molecules that modify their folding under even minor genetic or environmental variations. Indeed, under normal conditions, the rate of misfolding of serpins is high and unfolded serpins must be degraded by the proteasome system. Our aim was to study the effects of bortezomib, a proteasome inhibitor, on conformationally sensitive serpins. The effects of bortezomib were analysed in patients with multiple myeloma, HepG2 cells, and Swiss mice, as well as in vitro. Levels, anti-FXa activity, heparin affinity, and conformational features of antithrombin, a relevant anticoagulant serpin, were analysed. Histological, ultrastructural features and immunohistological distribution of antithrombin and a1-antitrypsin (another hepatic serpin) were evaluated. We also studied the intracellular accumulation of conformationally sensitive (fibrinogen) or non-sensitive (prothrombin) hepatic proteins. The inhibition of the proteasome caused intracellular accumulation and aggregation of serpins within the endoplasmic reticulum that was associated with confronting cisternae and Mallory body formation. These effects were accompanied by a heat stress response. Bortezomib also increased the levels of intracellular fibrinogen, but has no significant effect on prothrombin. Finally, bortezomib had only minor effects on the mature circulating antithrombin, with increased amounts of latent antithrombin in plasma. These results suggest that the impairment of proteasomal activities leads to an intracellular accumulation of conformationally sensitive proteins and might facilitate the release of misfolded serpins into circulation where they adopt more stable conformations.

IGF-1 induces the epithelial-mesenchymal transition via Stat5 in hepatocellular carcinoma

“…In recent years, the 5-year overall survival rate of HCC patients accounts for nearly 15% [ 4 ]. In addition, patients suffered from different situations, iincluding resistance to chemo-radiotherapy, metastatic tendencies, and diagnosis at advanced stages, which lead to low survival rate and poor life status [ 5 – 8 ]. Thus, it is essential to hunt for a novel way to minimize the progression of HCC.…”

UPR Pathways Combine to Prevent Hepatic Steatosis Caused by ER Stress-Mediated Suppression of Transcriptional Master Regulators

“…Remarkably, the proteasome inhibitor bortezomib, which is used clincally to treat multiple myeloma, led to lipid accumulation, as seen by ADRP upregulation (Figure 7A). Published reports suggest possible hepatoxicity of bortezomib (Hernandez-Espinosa et al, 2008; Rosinol et al, 2005). In addition, ADRP and C-JUN upregulation, and suppression of lipogenic genes, were also seen as a consequence of overexpression of the misfolding-prone Factor VIII clotting protein (Figure S12).…”

Identification of a novel alpha1-antitrypsin variant

“…Among the novel pharmacological options tested so far, the use of drugs targeting the regulation of autophagy (carbamazepine) [12] or proteasome function (bortezomib) [13] have been proposed. An attractive strategy, in this well characterized monogenic disease, is represented by gene therapy, particularly for patients with pulmonary dysfunction, where augmentation of functional A1AT levels in plasma might slow down respiratory disease development.…”